



Via E-Mail (AGO.highcostprescriptiondrugs@vermont.gov)

December 27, 2021

TJ Donovan
Attorney General
Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609

Re: Notice of New Prescription Drug to Market

Dear Mr. Donovan:

Pursuant to 18 VT. Stat. Ann. § 4637(b), this letter shall serve as notice that argenx released VYVGART™ (NDC 73475-3041-5), “a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program” on December 27, 2021. The product’s wholesale acquisition cost is \$5,950.00.

18 VT. Stat. Ann. § 4637 does not currently define “release of the drug in the commercial market.” Further, argenx is not aware of any guidance issued by the Vermont Attorney General’s Office or any Vermont regulation that defines “release of the drug in the commercial market” for the purpose of 18 VT. Stat. Ann. § 4637. argenx interprets “release of the drug in the commercial market” to mean when argenx makes a drug available for order.

Please contact René Edwards, Director, Government Price Reporting, at redwards@argenx.com if you have any questions.

Sincerely,

DocuSigned by:

William Richards

D63808F86C5E4DB...

William Richards
Vice President, US Market Access